本文選題：糖尿病腎病　切入點(diǎn)：心血管疾病　出處：《山東醫(yī)藥》2017年46期 　論文類型：期刊論文

【摘要】：目的探討厄貝沙坦聯(lián)合阿托伐他汀治療早期糖尿病腎病(DN)合并心血管疾病患者的療效。方法選取早期DN合并心血管疾病患者90例,分為觀察組、對照1組、對照2組各30例。每組均予控制血壓、控制血糖、預(yù)防感染及限制蛋白質(zhì)攝入等常規(guī)治療,對照1組予厄貝沙坦150 mg,1次/d口服;對照2組予阿托伐他汀40mg,1次/d口服;觀察組將阿托伐他汀與厄貝沙坦聯(lián)用。各組均連用6個(gè)月。治療后評價(jià)臨床療效,計(jì)算總有效率。治療前后檢測血壓(SBP、DBP)。治療前后抽空腹靜脈血,檢測血脂指標(biāo)(包括TG、TC、LDL-C、HDL-C)及血清B型腦鈉肽(BNP)、同型半胱氨酸(Hcy)、肌鈣蛋白I(c Tn I)、超敏C反應(yīng)蛋白(hs-CRP)水平。結(jié)果觀察組總有效率高于對照1、2組(P均0.05)。治療后,觀察組SBP、DBP均低于對照1、2組(P均0.05);觀察組TC、TG、LDL-C水平均低于對照1、2組,HDL-C均高于對照1、2組(P均0.05);觀察組血清BNP、HCY、cTnⅠ、hs-CRP水平均低于對照1、2組(P0.05或0.01)。結(jié)論厄貝沙坦聯(lián)合阿托伐他汀治療合并心血管疾病的早期DN患者可以提高臨床療效,降低血壓以及改善血脂水平,且可降低血清BNP、HCY、cTnⅠ、hs-CRP水平。
[Abstract]:Objective to investigate the efficacy of irbesartan combined with Atto vastatin in the treatment of early diabetic nephropathy (DN) with cardiovascular disease. Methods 90 patients with early DN complicated with cardiovascular disease were divided into observation group and control group. Control group (n = 30) received routine therapy such as controlling blood pressure, controlling blood glucose, preventing infection and limiting protein intake. Control group 1 was given irbesartan 150 mg / d once a day, control group 2 was given once a / d Atto vastatin 40 mg / d. The observation group was treated with Atto vastatin and irbesartan for 6 months. The clinical effect was evaluated and the total effective rate was calculated after treatment. The blood pressure was measured before and after treatment, and the abdominal venous blood was emptied before and after treatment. The serum lipids (including TGG, TCU, LDL-C, HDL-C), B type brain natriuretic peptide (BNPP), homocysteine cystatin (Hcyl), troponin I (c Tn), hypersensitive C-reactive protein (hs-CRP) were measured. Results the total effective rate of the observation group was higher than that of the control group (P 0.05). After treatment, the total effective rate of the observation group was higher than that of the control group (P < 0.05). In the observation group, the levels of SBP and DBP were lower than those in the control group (P < 0.05), the LDL-C levels in the observation group were lower than those in the control group (n = 12), the levels of HDL-C in the observation group were higher than those in the control group (P < 0.05), and the serum levels of BNP-HCYTn 鈪，

本文編號：1610177